These exciting findings point to the possibility that this smaller N-terminus peptide, based on its ability to interfere with the Bcl2-caspase 8 interaction, can be exploited as a potential therapeutic in disease states, such as cancer, where augmentation of the apoptotic cascade is clinically beneficial. The gene discussed is BCL2; the disease is cancer.